Share on X WhatsApp Email

Unclaimed profile

Lixte Biotechnology Holdings Inc 💀

$LIXT · Other · 🇺🇸 United States

Overview Holdings Proof of Reserves Reviews News Predictions

Visit Embed Report 📡 -- No Signal

LIXTE Biotech Holdings Inc. (NASDAQ: $LIXT) and Liora Technologies are advancing a multi-modal cancer platform, combining the LiGHT proton therapy system with LB-100 to potentially improve treatment precision and outcomes for patients. Read more: https://t.co/SZnyyr7Q3A https://t.co/O3mZYLVrsU

LIXTE Biotech Holdings Inc. ( $LIXT ) has appointed Sidney Braun as CEO of Liora Technologies, bringing 20+ years of global healthcare and strategic advisory experience to advance the LiGHT proton therapy platform. Read more: https://t.co/7XN2JlDQui #BioTech #Healthcare https://t.co/VkFr4Dp1nF

LIXTE Biotech Holdings Inc. has acquired Liora Technologies, adding the LiGHT proton therapy platform to advance precision cancer care and expand our integrated oncology innovation strategy. Read more: https://t.co/PJAxPCIlDR #Biotech #CancerResearch $LIXT https://t.co/sczxr87NWq

We’ve acquired Liora Technologies, bringing the proprietary LiGHT proton therapy system into the LIXTE family. Paired with LB-100, we’re advancing precision radiotherapy + combination cancer care to set a new standard in treatment. Read more: https://t.co/UR3t2C3F1J #therapy https://t.co/9cBqN9i0lc

Read more about our #LB100 cancer trials in collaboration with GSK and Roche in @PharmaNowGlobal. $LIXT https://t.co/6YU0Uw95Wn

over 1 year ago

Great news … the @LurieCancer of @NorthwesternU has been added as a second site in a clinical trial combining our LB-100 with GSK’s Dostarlimab to treat ovarian clear cell cancer. $LIXT #LB100 https://t.co/b51ghhF9FR https://t.co/FdVRmkmIAq

over 1 year ago

Click the video link below to learn more about our ovarian cancer trial with @GSK conducted by @MDAndersonNews. $LIXT #LB100 #dostarlimab https://t.co/r3ct1QKv1E

almost 2 years ago

In case you missed it, click below to watch a replay of CEO Bas van der Baan present at the Investor Summit Group Summer 2024 Virtual Conference. $LIXT https://t.co/IABhTRpUvF https://t.co/c6lHt3rqgy

about 2 years ago

This morning we announced that we received a patent allowance from the @uspto titled, "Oxabicycloheptanes for Modulation of Immune Response,” for combining our hashtag #LB100 compound with various innovative #cancer immunotherapies. $LIXT #Lixte https://t.co/VjcvCZD6Of https://t.co/mUSYkszE7Q

about 2 years ago

NEWS ALERT: This morning we announced the dosing of the first patient of a new clinical trial with @NKI_nl and @Roche for treatment of metastatic colorectal cancer. $LIXT #LB100 #cancertreatment https://t.co/l6mqvnqKt4

about 2 years ago

Holdings

-

/21ᴍ

Verified

0%

- on-chain

Avg Buy Price

$115,537

per BTC

Value

$0

USD

No holdings data

About Lixte Biotechnology Holdings Inc

Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) is a clinical-stage pharmaceutical company focused on developing cancer treatments. The company's research centers on protein phosphatase inhibitors as potential therapies for various cancers.

Lixte Biotechnology does not hold Bitcoin on its corporate balance sheet. The company is a small-cap biotech firm focused entirely on oncology drug development, with no involvement in the cryptocurrency or digital asset space.

Heroes · Blog · Ranking · FAQ · About · + Add ·

No Treasury Data

Lixte Biotechnology Holdings Inc has no reported Bitcoin treasury yet.

Back to profile

Treasury Report